Genetic Factors in Adverse Drug Reactions: Understanding the Underlying Mechanisms

Rose Hughes^*
*Correspondence: Rose Hughes, Department of Chemistry in Pharmaceutical Sciences, Complutense University of Madrid, Madrid, Spain, Email:

Introduction

Adverse Drug Reactions (ADRs) represent a significant challenge in clinical medicine, contributing to patient morbidity, mortality and increased healthcare costs. While many ADRs can be attributed to factors such as drug interactions, dosage errors and pre-existing conditions, genetic variations play a crucial role in the variability of drug responses among individuals. Understanding the genetic factors that contribute to ADRs is essential for improving drug safety, personalizing treatment regimens and minimizing the risks associated with drug therapy. Genetic polymorphisms in drug-metabolizing enzymes, drug transporters, receptors and immune system-related genes are among the key factors that can influence how a patient responds to a given drug, determining both the efficacy and toxicity of the treatment. These insights not only help identify patients who may be at greater risk of experiencing ADRs but also enable the development of safer, more effective drugs with fewer side effects. As research in this area continues to evolve, understanding the genetic basis of ADRs will be integral to improving patient outcomes, optimizing drug use and advancing the broader field of personalized healthcare [1].

Description

Adverse Drug Reactions (ADRs) are unintended and harmful responses to medications that occur at normal doses used for prevention, diagnosis, or treatment of a disease. While ADRs are a well-recognized aspect of drug therapy, the reasons behind why certain individuals experience these reactions, while others do not, are complex and multifactorial. Genetic factors have become increasingly recognized as key contributors to this variability in drug response. Over the years, research in pharmacogenomics, which explores how genetic differences affect the way individuals respond to drugs, has highlighted the critical role that genetic variations play in determining the likelihood, severity and type of ADRs a person may experience. One of the most well-established genetic factors in ADRs involves polymorphisms in genes encoding drug-metabolizing enzymes. These enzymes, primarily located in the liver, are responsible for the biotransformation of drugs into their active or inactive forms. Variations in the genes encoding these enzymes can result in altered enzyme activity, leading to differences in the rate at which drugs are metabolized and consequently, differences in drug concentrations in the body [2].

For example, individuals with certain genetic variations may metabolize a drug more quickly, resulting in suboptimal drug concentrations and therapeutic failure, while others may metabolize the same drug more slowly, leading to the accumulation of toxic levels and an increased risk of ADRs. The most well-known example of this phenomenon is the variation in Cytochrome P450 (CYP) enzymes, a large family of enzymes responsible for the metabolism of many commonly used drugs. The polymorphisms in the CYP450 family have been well-studied in relation to ADRs. CYP2D6, for example, is involved in the metabolism of a wide range of drugs, including antidepressants, beta-blockers and antipsychotics. There are several genetic variants of CYP2D6, including those that result in ultra-rapid, extensive, intermediate, or poor metabolizer phenotypes. Ultra-rapid metabolizers may metabolize drugs too quickly, leading to lower-than-expected drug levels and treatment failure. On the other hand, poor metabolizers may experience toxic side effects due to the slow breakdown of drugs in their system. Variants of other CYP enzymes, such as CYP2C9 and CYP2C19, are also associated with ADRs related to anticoagulants (e.g., warfarin) and antiplatelet agents, respectively. The identification of these genetic variants allows for dose adjustments and the selection of alternative medications, reducing the risk of ADRs and improving therapeutic outcomes. For instance, individuals with variants of the TPMT gene may have decreased enzyme activity, which can lead to toxic levels of thiopurine drugs (used in the treatment of leukemia and autoimmune diseases) and result in life-threatening adverse reactions, including bone marrow suppression. In contrast, individuals with a high level of TPMT activity may metabolize these drugs too quickly, leading to treatment failure [3].

In addition to drug-metabolizing enzymes, genetic variations in drug transporters can also contribute to ADRs. Drug transporters are proteins that mediate the movement of drugs across cell membranes, influencing the absorption, distribution and elimination of drugs. Polymorphisms in genes encoding drug transporters can affect how efficiently drugs are absorbed in the gastrointestinal tract, how they are distributed to different tissues and how they are eliminated by the kidneys and liver. Genetic variations can also affect drug targets, such as receptors and enzymes that mediate the therapeutic effects of drugs. These variations can lead to altered drug efficacy or increase the risk of ADRs. For example, genetic mutations in the serotonin receptor 2C (5- HT2C) gene have been associated with an increased risk of adverse effects from certain antidepressants, such as weight gain and sexual dysfunction. Similarly, mutations in the Epidermal Growth Factor Receptor (EGFR) gene have been shown to affect the efficacy and toxicity of targeted therapies for cancer. In some cases, genetic polymorphisms in drug targets may influence the binding of a drug to its receptor, altering its effectiveness or the likelihood of experiencing side effects. Understanding these variations can help identify individuals who may be at higher risk for ADRs and allow clinicians to tailor treatments accordingly [4].

Genetic variations in immune system-related genes can also contribute to ADRs, particularly in the context of drug hypersensitivity reactions. Hypersensitivity reactions are immune-mediated responses to drugs that can range from mild skin rashes to life-threatening anaphylaxis. Similarly, genetic variations in the HLA region have been implicated in adverse reactions to other drugs, including antibiotics (e.g., penicillin) and anticonvulsants (e.g., carbamazepine), underscoring the importance of genetic testing for predicting and preventing these potentially severe drug reactions. Despite the potential benefits, the widespread implementation of pharmacogenomic testing in clinical practice faces several challenges. One major challenge is the complexity of the genetic factors involved in drug response, as many ADRs are influenced by multiple genetic variants in combination with environmental factors. Additionally, genetic testing is not universally available and the cost of testing may be a barrier to its widespread adoption. Furthermore, not all drug responses are solely determined by genetics; environmental factors, such as diet, lifestyle and other medications, can also play a role in ADRs. As a result, pharmacogenomic testing must be considered as part of a broader, holistic approach to patient care that includes careful clinical assessment and monitoring [5].

Conclusion

In conclusion, genetic variations play a critical role in the occurrence and severity of adverse drug reactions, influencing drug metabolism, transport, target interactions and immune responses. Pharmacogenomics has provided valuable insights into the mechanisms underlying ADRs and offers the potential to reduce the occurrence of these reactions by enabling personalized drug therapy. As research in pharmacogenomics continues to evolve and more genetic variants are identified, the ability to predict and manage ADRs will improve, leading to safer, more effective drug treatments. The integration of pharmacogenomic testing into routine clinical practice holds great promise for enhancing patient safety, optimizing drug therapy and advancing the field of personalized medicine. However, challenges remain in translating these discoveries into everyday healthcare and ongoing efforts are needed to improve access to genetic testing, educate healthcare providers and incorporate genetic information into clinical decision-making. Ultimately, the goal is to improve patient outcomes by reducing the risk of ADRs and providing treatments that are tailored to each individual’s genetic profile.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Chan, Sze Ling, Xiaohui Ang, Levana L. Sani and Hong Yen Ng, et al. "Prevalence and characteristics of adverse drug reactions at admission to hospital: A prospective observational study." Br J Clin Pharmacol 82 (2016): 1636-1646.

   Google Scholar, Crossref, Indexed at

2. Alessandrini, Marco, Mamoonah Chaudhry, Tyren M. Dodgen and Michael S. Pepper. "Pharmacogenomics and global precision medicine in the context of adverse drug reactions: Top 10 opportunities and challenges for the next decade." Omics A J Integr Biol 20 (2016): 593-603.

   Google Scholar, Crossref, Indexed at

3. Bloomfield, Hanna E., Nancy Greer, Amy M. Linsky and Jennifer Bolduc, et al. "Deprescribing for community-dwelling older adults: A systematic review and meta-analysis." J Gen Intern Med 35 (2020): 3323-3332.

   Google Scholar, Crossref, Indexed at

4. Aronson, Jeffrey K. and Robin E. Ferner. "Joining the DoTS: New approach to classifying adverse drug reactions." Bmj 327 (2003): 1222-1225.

   Google Scholar, Crossref, Indexed at

5. Whitman andrew, Paige Erdeljac, Caroline Jones and Nicole Pillarella, et al. "Managing polypharmacy in older adults with cancer across different healthcare settings." Drug Healthc Patient Saf (2021): 101-116.

   Google Scholar, Crossref, Indexed at